Market Intelligence, Clinical Progress, and High-Purity Reagents for TGF-β Superfamily Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for INHBA (Activin A) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Ligand | INHBA (Activin A) Recombinant Homodimer High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed by Mass Spec. |
View INHBA Products |
| Decoy Receptor | ACVR2B (ActRIIB)-Fc Fusion Protein Biosimilar grade for ligand trap validation and competitive binding studies. |
View ACVR2B Products |
| Alternative Receptor | ACVR2A (ActRIIA)-Fc Fusion Protein Sequence Verified. For comparative binding studies and decoy receptor controls. |
View ACVR2A Products |
| Natural Antagonist | Follistatin (FST) Recombinant Protein High purity reference standard (FST-288 or FST-315). |
View FST Products |
| Paralog Control | INHBB (Activin B) Recombinant Protein For selectivity counter-screening; sequence identity ~65% to INHBA. |
View INHBB Products |
| Type I Receptor | ALK4 (ACVR1B) Recombinant Protein For ternary complex formation assays and receptor signaling studies. |
View ACVR1B Products |
| Gene Delivery | INHBA Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and secretion modeling. |
View INHBA Products |
| Validator | INHBA siRNA Set Sequence-verified; for target specificity verification and knockdown validation. |
View INHBA Products |
| Benchmark Ab | Anti-INHBA / Anti-Activin A (Garetosmab Sequence Reference) Recombinant neutralizing positive control for blockade assays. |
View INHBA Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Correct homodimer folding & disulfide linkage | HEK293 expression system supports native disulfide bond formation; Purity >95%. Theoretical MW annotated and verified by Mass Spec. |
| Activin A vs BMP Selectivity (BMP9/10 also bind ACVR2B) | Homolog Panel Available: INHBA, INHBB, GDF11, BMP9, BMP10 proteins with >95% purity and sequence-verified identity for off-target profiling. |
| Non-Human Primate Toxicology Bridging | Human/Cynomolgus/Rhesus Orthologs: Sequence-aligned proteins with verified endotoxin levels <0.1EU/µg for GLP-grade studies. |
| Ligand-Receptor Binding Kinetics | SPR/BLI Ready: Tags removed or biotin-labeled options available; Native disulfide bond formation verified. |
| Cell-Based Reporter Assay Setup | CAGA-Luc Reporter Cell Line Compatible: High-activity INHBA protein validated for Smad2/3 pathway activation with EC50 consistency. |
| Mechanistic Validation | Decoy Receptor Controls: ACVR2A-Fc and ACVR2B-Fc available as positive blocking controls for mechanism-of-action confirmation. |
| Subfamily Counter-Screening (INHBB, GDF8, GDF11) | Extended TGF-beta superfamily homolog panel proteins; Sequence Verified; Endotoxin Controlled. |
| Absence of Neutralizing Standard & Off-Target False Positives | Clinical Benchmark Antibody (Garetosmab-class) included; Validated siRNA set for target-specificity knockdown control. |
Live INHBA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Activin A)
- ➤ Sotatercept (ACVR2A-Fc) Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for INHBA (Activin A) pathway therapeutics is intensifying, with major players shifting focus from broad ActRII traps to ligand-selective neutralizing antibodies and tissue-specific delivery. First-generation molecules such as sotatercept (ActRIIA-Fc, approved for PAH) and luspatercept (ActRIIB-Fc, for anemia) have established clinical proof-of-concept, while bimagrumab (anti-ActRII antibody) is advancing in obesity and sarcopenia. The next wave of R&D targets highly selective INHBA inhibition to mitigate BMP-related toxicities, combination regimens with immune checkpoint inhibitors, and refined delivery for cachexia and fibrosis. Emerging strategies include bispecific decoy receptors and small-molecule receptor kinase inhibitors aimed at tumor-microenvironment modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ActRII-Fc Fusion (Ligand Trap) | Acceleron (BMS), Merck (sotatercept), Pfizer | Pulmonary Arterial Hypertension, Myelofibrosis, Anemia (β-thalassemia/MDS) | Ligand Binding Selectivity (Need INHBA vs BMP9/BMP10 panel) |
| Anti-Activin A Monoclonal Antibody | Regeneron (garetosmab), Versant/Roche (Scholar Rock) | Cancer Cachexia, FOP, Myelofibrosis | Epitope Mapping & Selectivity vs INHBB (Need high-purity INHBA & ortholog panel) |
| Anti-ActRII Antibody | Novartis (bimagrumab), Versanis (now Lilly) | Obesity, Sarcopenia, Cachexia | Functional Blockade Assay (Need INHBA + ACVR2B cell system) |
| Bispecific/Multispecific Decoy | Early-stage biotech | Fibrosis, Muscle-preserving obesity | Heterodimer Validation (Need multiplex ligand panel & receptor combination assays) |
| Small Molecule (Receptor Kinase) / Peptide Inhibitors | Various biopharma, Academic | Oncology, Fibrosis, Reproductive Medicine | Selectivity Assay & Competition Binding (Need high-purity proteins & pathway-specific cellular assays) |